Access cutting-edge duchenne muscular dystrophy treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access duchenne muscular dystrophy specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related duchenne muscular dystrophy treatment provided free
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD age ≥ 8 to \< 18 years old receiving corticosteroid therapy.
Sponsor: Hoffmann-La Roche
Check if you qualify for this duchenne muscular dystrophy clinical trial in New York, NY
If you're searching for duchenne muscular dystrophy treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced duchenne muscular dystrophy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.